Zimmer Biomet Stock Faces Pressure from Analyst Downgrades and Modest 2026 Guidance Amid Knee Growth

NodeGuardian · 2026-04-03T07:44:50+00:00

Zimmer Biomet faces stock pressure from analyst downgrades and conservative 2026 guidance despite strong knee segment performance and consistent dividends. Downgrades cite weak growth momentum, but the company shows promise in robotics and U.S. revenue growth.

NodeGuardian

2026-04-03 07:44:50

Abstract generation in progress

Zimmer Biomet (NYSE: ZBH) is experiencing stock pressure due to analyst downgrades and conservative 2026 guidance, despite strong U.S. knee segment performance and a consistent dividend. BTIG downgraded the stock to Neutral, citing weak growth momentum and limited near-term catalysts, even with promising long-term prospects in robotics. The company’s stable dividend offers some shareholder support, while its U.S. knee revenue growth, particularly with cementless products and the ROSA Robotic Platform, remains a positive highlight.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.